Pioneering Tumor-treating Fields: A Breakthrough Approach for Pediatric Brain Tumors

Bhavya Fenoy^*
*Correspondence: Bhavya Fenoy, Department of Neuro-Oncology, Russian People’s Friendship University, 121359 Moscow, Russia, Email:

Introduction

The landscape of pediatric oncology is continually evolving, with advancements in therapeutic modalities at the forefront of this progress. Among these, Tumor-Treating Fields (TTFields) therapy has emerged as a groundbreaking approach, offering a novel and non-invasive alternative for the treatment of pediatric brain tumors. This innovative modality represents a paradigm shift in the way we address malignancies affecting the delicate neural structures of young patients. As we delve into the realm of TTFields therapy, the potential for enhanced efficacy and reduced adverse effects sparks a renewed sense of hope in the challenging terrain of pediatric neuro-oncology. Pediatric brain tumors present unique challenges in terms of diagnosis and treatment due to the developing nature of the young brain. The treating fields for pediatric brain tumors encompass a multidisciplinary approach involving pediatric neuro-oncologists, neurosurgeons, radiation oncologists and other specialists. The primary treatment modalities for pediatric brain tumors include surgery, radiation therapy and chemotherapy, with the selection and sequence of these interventions depending on the specific type and location of the tumor [1,2].

Description

Tumor-Treating Fields therapy involves the application of low-intensity, alternating electric fields to disrupt the division of cancer cells. For pediatric brain tumors, this therapy represents a departure from conventional treatment strategies such as surgery, chemotherapy and radiation. The device generating these fields is designed to be portable, allowing for a degree of flexibility in its use, which is particularly advantageous for the dynamic and often unpredictable nature of pediatric patients' lives. The mechanism of action, centered on impeding cell division through interference with mitotic spindle formation, distinguishes TTFields therapy from traditional interventions and positions it as a promising adjunct or even primary treatment modality for certain pediatric brain tumors. Clinical studies have illuminated the potential benefits of TTFields therapy in terms of both efficacy and safety for pediatric patients. Initial results suggest not only a favorable tumor response but also a relatively low incidence of adverse effects, a critical consideration in the context of developing brains. The modality's non-invasiveness and lack of systemic toxicity further underscore its appeal as a therapeutic option for children facing the formidable challenge of brain tumors. As we delve deeper into the specifics of TTFields therapy for pediatric brain tumors, the ongoing research endeavors and clinical trials become pivotal in establishing its role within the broader spectrum of pediatric oncology [3,4].

Radiation therapy is another key component in the treatment of pediatric brain tumors. However, the developing brain is more sensitive to radiation and the potential long-term cognitive effects must be carefully considered. Advanced techniques, such as proton therapy, may be utilized to target the tumor more precisely, reducing the impact on surrounding healthy tissue and minimizing long-term side effects. Chemotherapy is often employed, either alone or in combination with surgery and/or radiation therapy. The choice of chemotherapy agents depends on the tumor type and the child's overall health. Pediatric oncologists strive to find a balance between effectively treating the tumor and minimizing the impact on the child's quality of life. In recent years, there has been a growing emphasis on personalized and targeted therapies for pediatric brain tumors. Advances in molecular profiling and genetic testing enable oncologists to identify specific characteristics of the tumor, allowing for more tailored and effective treatment strategies. Immunotherapy, which harnesses the body's immune system to target cancer cells, is also being explored as a promising avenue in the treatment of pediatric brain tumors. Surgery plays a crucial role in the management of pediatric brain tumors. Neurosurgeons aim to remove as much of the tumor as possible while preserving surrounding healthy brain tissue. The intricacies of pediatric neurosurgery require a delicate balance to minimize potential damage to the developing brain, especially in critical areas responsible for functions such as motor skills, language and cognition [5,6].

Conclusion

In conclusion, the advent of Tumor-Treating Fields therapy marks a transformative chapter in the management of pediatric brain tumors. The unique approach of harnessing electric fields to impede cancer cell proliferation offers a promising avenue for improved outcomes, reduced treatment-related side effects and enhanced quality of life for young patients. While the field is still evolving, the preliminary findings and ongoing research endeavors contribute to a sense of optimism within the pediatric oncology community. As we continue to unravel the intricacies of TTFields therapy, its integration into the comprehensive care of pediatric brain tumor patients holds the potential to redefine treatment paradigms and pave the way for a more hopeful future in the face of this formidable medical challenge. Comprehensive and long-term follow-up care is crucial for children who have undergone treatment for brain tumors. Regular monitoring helps identify any potential late effects of treatment and provides support for the child's overall well-being, including cognitive and emotional aspects. As research continues to advance, the goal is to improve outcomes for children with brain tumors while minimizing the long-term impact on their quality of life.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Ostrom, Quinn T., Nirav Patil, Gino Cioffi and Kristin Waite, et al. "CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017." Neuro-oncology 22 (2020): iv1-iv96.

   Google Scholar, Crossref, Indexed at

2. Brodbelt, Andrew, David Greenberg, Tim Winters and Matt Williams, et al. "Glioblastoma in England: 2007–2011." Eur J Cancer 51 (2015): 533-542.

   Google Scholar, Crossref, Indexed at

3. Stupp, Roger, Monika E. Hegi, Warren P. Mason and Martin J. Van Den Bent, et al. "Effects of radiotherapy with concomitant and adjuvant temozolomide vs. radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial." Lancet Oncol 10 (2009): 459-466.

   Google Scholar, Crossref, Indexed at

4. Stupp, Roger, Sophie Taillibert, Andrew Kanner and William Read, et al. "Effect of tumor-treating fields plus maintenance temozolomide vs. maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial." JAMA 318 (2017): 2306-2316.

   Google Scholar, Crossref, Indexed at

5. Cohen, Kenneth J., Ian F. Pollack, Tianni Zhou and Allen Buxton, et al. "Temozolomide in the treatment of high-grade gliomas in children: A report from the Children's Oncology Group." Neuro-oncology 13 (2011): 317-323.

   Google Scholar, Crossref, Indexed at